Maven Securities’s Grace Therapeutics GRCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-200,000
Closed -$454K – 657
2026
Q2
$454K Buy
+200,000
New +$553K 0.01% 305

Other funds holding GRCE

Maven Securities's GRCE Position: Q3 2026 in Review

Maven Securities sold out of Grace Therapeutics (GRCE) in Q3 2026, closing a stake of 200,000 shares — an estimated $454K sold.

Maven Securities first reported a position in GRCE in Q2 2026 and held it in 1 quarter. The position peaked at $454K in Q2 2026. 38 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

  • Maven Securities reported no remaining Grace Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Maven Securities sold 200,000 Grace Therapeutics shares in Q3 2026, an estimated $454K.
  • Maven Securities first reported a position in Grace Therapeutics in Q2 2026 and held it in 1 quarter.
  • Maven Securities's Grace Therapeutics position peaked at $454K in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Maven Securities's 13F filing for Q3 2026, filed 13 Nov 2026.